Journal: Toxicological Sciences

Article Title: Assessing Effects of BHV-0223 40 mg Zydis Sublingual Formulation and Riluzole 50 mg Oral Tablet on Liver Function Test Parameters Utilizing DILIsym

doi: 10.1093/toxsci/kfaa019

Figure Lengend Snippet: Parameters Used in the DILIsym PBPK Submodel for Riluzole

Article Snippet: The structure of the DILIsym PBPK submodel has been discussed in detail elsewhere ( Howell et al. , 2012 ; Woodhead et al. , 2012 , ).

Techniques: Clinical Proteomics, Protein Binding, Molecular Weight

Journal: Clinical Pharmacology and Therapeutics

Article Title: Systems pharmacology modeling of drug‐induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters

doi: 10.1002/cpt.619

Figure Lengend Snippet: Diagrams of hepatobiliary disposition of bilirubin ( a ) and the bilirubin submodel structure within DILIsym ( b ). CB, conjugated bilirubin; DJS, Dubin‐Johnson Syndrome; GS, Gilbert's Syndrome; HC, hepatocytes; MRP, multidrug resistance‐associated protein; OATP, organic anion transporting polypeptide; RBC, red blood cell; RS, Rotor Syndrome; UB, unconjugated bilirubin; UGT, UDP glucuronosyltransferase.

Article Snippet: Physiological parameters for tissue volumes and blood flows in the PBPK submodel of DILIsym were published elsewhere.

Techniques:

Journal: CPT: Pharmacometrics & Systems Pharmacology

Article Title: Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym ® , a Mechanistic Model of Drug‐Induced Liver Injury

doi: 10.1002/psp4.12053

Figure Lengend Snippet: List of parameters varied in the SimPops™ and results of multiple‐regression analysis in SimPops™ administered tolcapone (200 mg t.i.d. for 1 week)

Article Snippet: Via the use of PBPK submodels developed to describe the disposition of tolcapone and entacapone, DILIsym ® predicted lower hepatic exposure for entacapone than for tolcapone for clinically relevant dosing regimens of each compound.

Techniques: